FDA grants accelerated approval for GlaxoSmithKline's TYKERB

[News]

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for a new combination regimen using TYKERB® (lapatinib) as a first-line, all-oral treatment for women with metastatic breast cancer.

More... (http://www.news-medical.net/news/20100129/FDA-grants-accelerated-approval-for-GlaxoSmithKlines-TYKERB.aspx)